Malignant hyperthermia: Excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects

Physiological Reviews

Volumn 76, Issue 2, 1996, Pages 537-592

  Mickelson, James R ^a   Louis, Charles F ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL;

EXCITATION CONTRACTION COUPLING; HUMAN; MALIGNANT HYPERTHERMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SWINE;

ANIMALS; CALCIUM; CALCIUM CHANNELS; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUSCLE, SKELETAL;

EID: 0029896831     PISSN: 00319333     EISSN: None     Source Type: Journal    
DOI: 10.1152/physrev.1996.76.2.537     Document Type: Review

References (434)

1. ADAMS, B., T. TANABE, A. MIKAMI, S. NUMA, AND K. BEAM. Intramembrane charge movement restored in dysgenic muscle by injection of dihydropyridine receptor complementary DNAs. Nature Land. 346: 569-572, 1990.
2. --ATPase content in skeletal muscle of patients susceptible to malignant hyperthermia (Abstract), J. Physiol. Lond. 335: 15P, 1984.
3. ADEOLA, O., R. O. BULL, J. D. HOUSE, AND R J. O'BRIEN. Regional brain neurotransmitter concentrations in stress-susceptible pigs. J. Amm. Sci. 71: 968-974, 1993.
4. ADNET, P. J., N. L. BROMBERG, G. HAUDECOEUR, I. KRIVOSIC, M. M. ADAMANTIDIS, H. REYFORD, N. BELLO, AND R. M. KRIVOSIC-HORBER. Fiber-type caffeine sensitivities in skinned muscle fibers from humans susceptible to malignant hyperthermia. Anesthesiology 78: 168-177, 1993.
5. ADNET, P. J., R. M. KRIVOSIC-HORBER, M. M. ADAMANTIDIS, G. HAUDECOEUR, H. REYFORD, AND B. A. DUPUIS. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia. Br. J. Anaesth. 64: 64-66, 1990.
6. ADNET, P. J., R. M. KRIVOSIC-HORBER, M. M. ADAMANTIDIS, G. HAUDECOEUR, H. REYFORD, AND M. IMBENOTTE. Effect of Bay K 8644 on the magnitude of isoflurane and halothane contracture of skeletal muscle from patients susceptible to malignant hyperthermia. Anesthesiology 76: 544-549, 1992.
7. ADNET, P. J., R. M. KRIVOSIC-HORBER, M. M. ADAMANTIDIS, H. REYFORD, C. CORDONNIER, AND G. HAUDECOEUR. Effects of calcium-free solution, calcium antagonists, and the calcium agonist BAY K 8644 on mechanical responses of skeletal muscle from patients susceptible to malignant hyperthermia, Anesthesiology 75: 413-419, 1991.
8. ADNET, P. J., R. M. KRIVOSIC-HORBER, G. HAUDECOEUR, M. M. ADAMANTIDIS, G. H. REYFORD, M. IMBENOTTE, AND C. CORDONNIER. Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia. Br. J. Anaesth 65: 791-795, 1990.
9. ADNET, P. J., R. M. KRIVOSIC-HORBER, G. HAUDECOEUR, H. G. REYFORD, M. M. ADAMANTIDIS, AND B. A. DUPUIS. Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle. Can. J. Anaesth. 37: 556-559, 1990.
10. AHERN, C. P., J. H. MILDE, AND G. A. GRONERT, Electrical stimulation triggers porcine malignant hyperthennia. Res. Vet. Sci. 39 257-258, 1985.
11. ALAMO, L., J. R. LOPEZ, L. PAPP, AND F. A, SRETER. Simultaneous measurement by means of ion-specific electrodes of free intracellular ionized calcium and magnesium in rabbit skeletal muscle. Muscle Nerve 9: 472-474, 1986.
12. ALDRETTE, J. A., AND B. A. BRITT. Second International Symposium on Malignant Hyperthennia. New York: Grune & Stratton, 1978, p. 1-560.
13. ALLEN, G. C., J. E. FLETCHER, F. J HUGGINS, P. A. CONTI, AND H. ROSENBERG. Caffeine and halothane contracture testing in swine using the recommendations of the North American Malignant Hyperthermia Group. Anesthesiology 72: 71-76, 1990.
14. ALLEN, P. D., J. F. RYAN, D. E. JONES, K. MABUCHI, A. VIRGA, J. ROBERTS, AND F. SRETER. Sarcoplasmic reticulum calcium uptake in cryostat sections of skeletal muscle from malignant hyperthermia patients and controls. Muscle Nerve 9: 474-475, 1986.
15. 2+ uptake and actomyosin ATPase (Abstract). Anesthesiology 3: S251, 1980.
16. ALTROGGE, D. M., D. G. TOPEL, M. A. COOPER, J. W. HALLBERG, AND D. D. DRAPER. Urinary and caudate nuclei catecholamine levels in stress-susceptible and normal swine. J. Anim. Sci. 51: 74-77, 1980.
17. ARAHATA, K, AND H. SUGITA. Dystrophin and the membrane hypothesis of muscular dystrophy. Trends Pharmacol. Sci. 10: 437-439, 1989.
18. ARAKI, M., A. TAKAGI, T. FUJITA, AND T. MATSUBARA. Porcine malignant hyperthermia: caffeine contracture of single skinned muscle fibers. Biomed. Res. 6: 73-78, 1985.
19. ARCHIBALD, A. L., AND P. IMLAH. The halothane sensitivity locus and its linkage relationships. Ann. Blood Groups Biochem. Gen. 16: 253-263, 1985.
20. ARTRU, A. A., AND G. A. GRONERT. Cerebral metabolism during porcine malignant hyperthermia. Anesthesiology 53: 121-126, 1980.
21. 2+ and activation mechanisms in skeletal muscle. Q. Rev. Biophys. 24: 1-73, 1991.
22. BACKMAN, E., C. LENNMARKEN, H. RUTBERG, AND K. G. HENRIKSSON. Skeletal muscle contraction characteristics in vivo in malignant hyperthermia susceptible subjects. Acta Neurol. Scand. 77: 278-282, 1988.
23. BALL, S. P., H. R. DORKINS, F. R. ELLIS, J. L. HALL, P. J. HALSALL, P. M. HOPKINS, R. F. MUELLER, AND A. D. STEWART. Genetic linkage analysis of chromosome 19 markers in malignant hyperthermia. Br. J. Anaesth. 70. 70-75, 1993.
24. BALL, S. P., AND K. J. JOHNSON. The genetics of malignant hyperthermia J. Med. Genet. 30: 89-93, 1993.
25. BANASZAK, L, N. WINTER, Z. XU, D. A. BERNLOHR, S. COWAN, AND T. A. JONES. Lipid binding proteins: a family of fatty acid and retinoid transport protein. Adv. Protein Chem. 45: 89-151, 1994.
26. BENDER, K., H. SENFF, T. F. WIENKER, C. SPIESS-KIEFER, AND F. LEHMANN-HORN. A linkage study of malignant hyperthermia (MH). Clin. Genet. 37: 221-225, 1990.
27. BIEGON, R. P, J. R. MICKELSON, AND C. F. LOUIS. Altered pH sensitivity of the ryanodine binding to sarcoplasmic reticulum of malignant hyperthermia susceptible pigs (Abstract). Biophys. J 57: 277a, 1990.
28. BLANCK, T. J. J. The volatile anesthetics increase calcium leakage from skeletal muscle sarcoplasmic reticulum. Minerva Anesthesiol. 60: 145-149, 1994.
29. 2- dependence of normal and malignant hyperthermia human muscle. Anesth. Analg. 60: 492-498, 1981.
30. BLANCK, T. J. J., C. V. PETERSON. B. BAROODY, V. TEGAZZIN, AND J. LOU. Halothane, enflurane and isoflurane stimulate calcium leakage from rabbit sarcoplasmic reticulum. Anesthesiology 76: 813-821, 1992.
31. 2+ release in mouse T-lymphoma cells. J. Biol. Chem. 270:17917-17922, 1995
32. 2+ ATPase genes: homologies and mechanistic implications of deduced amino acid sequences. Cell 44: 597-607, 1986.
33. 2+ release from sarcoplasmic reticulum. Fed. Eur. Biochem. Soc. Lett. 299: 57-59, 1992.
34. BRILLANTES, A.-M., K. ONDRIAS, A. SCOTT, E. KOBRINSKY, E. ONDRIASOVA, M. C. MOSCHELLA, T. JAYARAMAN, M. LANDERS, B. E. EHRLICH, AND A. R. MARKS. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 77: 513-523, 1994.
35. BRIMIJOIN, S. Molecular forms of acetylcholinesterase in brain, nerve and muscle: nature, localization and dynamics. Prog. Neurobiol. 21:291-322, 1993.
36. BRITT, B. A. Dantrolene: an update. In: Malignant Hyperthermia, edited by B. A. Britt. Boston, MA: Martinus Nijhoff, 1987, p. 325-368.
37. BRITT, B. A. Malignant Hyperthermia. Boston, MA: Martinus Nijhoff, 1987, 1-420.
38. BRITT, B. A., L. ENDRENYI, AND D. L. CADMAN. Calcium uptake into muscle of pigs susceptible to malignant hypertherrnia: in vitro and in vivo studies with and without halothane. Br. J. Anaesth. 47: 650-653, 1975.
39. BRITT, B. A., AND W. KALOW. Malignant hyperthermia: a statistical review. Can. Anesth. Soc. J. 17: 293-315, 1970.
40. BRITT, B. A, W. KALOW, A. GORDON, J. G. HUMPHREY, AND N. B. REWCASTLE. Malignant hyperthermia: an investigation of five patients. Can. Anaesth. Soc. J. 20: 431-467, 1973.
41. BRODY, I. Muscle contracture induced by exercise. A syndrome attributable to decreased relaxing factor. N. Engl. J. Med. 281: 187-192, 1969.
42. BROOKS, G. A., AND R. G. CASSENS. Respiratory functions of mitochondria isolated from stress susceptible and stress resistant pigs. J. Anim. Sci. 37: 688-691, 1973.
43. BROWNELL, A. K. W. Malignant hyperthermia: relationship to other diseases. Br. J. Anaesth. 60: 303-308, 1088.
44. BROWNELL, A. K. W., R. T. PAASUKE, A. ELASH, S. B. FOWLOW, C. G. F. SEAGRAM, R. J. DIEWOLD, AND C. FRIESEN. Malignant hyperthermia in Duchenne Muscular Dystrophy. Anesthesiology 58: 180-182, 1983.
45. BULL, R., AND J. J. MARENGO. Calcium-dependent halothane activation of sarcoplasmic reticulum calcium channels from frog skeletal muscle. Am. J. Physiol 266 (Cell Physiol. 35): C391-C396, 1994.
46. CAMPBELL, K. P., A. T. LEUNG, AND A. H. SHARP. The biochemistry and molecular biology of the dihydropyridine-sensitive calcium channel. Trends Neurol. Sci. 11: 425-430, 1988.
47. CAMPION, D. R., G. EIKLENBLOOM, AND R. G. CASSENS. Isometric contractile properties of skeletal muscle from stress susceptible and stress resistant pigs J. Anim. Sci. 39: 68-72, 1974.
48. CAMPION, D. R., J. C. OLSON, D. G. TOPEL, L. L. CHRISTIAN, AND D. L. KUHLERS. Mitochondrial traits of muscle from stress susceptible pigs. J. Anim. Sci. 41: 1314-1317, 1975.
49. CAMPION, D. R., D. G. TOPEL, AND L. L. CHRISTIAN. In vitro studies of mitochondrial and sarcoplasmic reticulum function in muscle of stress susceptible pigs. J. Anim. Sci. 43: 426-431, 1976.
50. 2+ release from sarcoplasmic reticulum of malignant hyperthermia susceptible pigs. Biochim. Biophys. Acta 1064: 175-183, 1991.
51. CASWELL, A. H., N. R. BRANDT, J. P. BRUNSCHWIG, AND S. PURKERSON. Localization and partial characterization of the oligomeric disulfide-linked molecular weight 95,000 protein (triadin) which binds the ryanodine and dihydropyridine receptors in skeletal muscle triadic vesicles. Biochemistry 30: 7507-7513, 1991.
52. CATTERALL, W. A. Functional subunit structure of voltage-gated calcium channels. Science Wash. DC 253: 1499-1500, 1991.
53. CHATEL, J. M., A. ANSELMET, F. M. VALLETTE, AND J. MASSOLIE. Multilevel regulation of acetylcholinesterase biosynthesis and maturation. Biochem. Soc. Trans. 22: 735-740, 1994.
54. CHEAH, K. S. Mitochondria and malignant hyperthermia In: Malignant Hyperthermia, edited by B. A. Britt. Boston, MA: Martinus Njjhoff, 1987, p. 79-102.
55. CHEAH, K. S., AND A. M. CHEAH. The trigger for PSE condition in stress-susceptible pigs. J. Sci. Food Agric. 27: 1137-1144. 1976.
56. CHEAH, K. S., AND A. M. CHEAH. Calcium movements in skeletal muscle mitochondria of malignant hyperthermic pigs. Fed. Eur. Biochem. Soc. Lett. 95: 307-310, 1978.
57. CHEAH, K. S., AND A. M. CHEAH. Mitochondrial calcium transport and calcium-activated phospholipase in porcine malignant hyperthermia. Biochim. Biophys. Acta 634: 70-84, 1981.
58. 2 and the interaction of mitochondria and sarcoplasmic reticulum in porcine malignant hyperthermia. Biochim. Biophys. Acta 638: 40-49, 1981.
59. 2+-induced uncoupling and free fatty acids. Int. J. Biochem. 21: 913-920, 1989.
60. CHEAH, K. S., A. M. CHEAH, J. E. FLETCHER, AND H. ROSENBERG. Calcium accumulation by sarcoplasmic reticulum in whole muscle homogenate preparations of malignant hyperthermia diagnostic patients and pigs. Acta Anaesthesiol. Scand. 34: 114-119, 1990.
61. 2- and meat quality in young and adult halothane-sensitive and halothane-insensitive British landrace pigs. Meat Sci. 17: 37-53, 1986.
62. 2+ release channel (ryanodine receptor) of rabbit skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 269: 22698-22704, 1994.
63. CHOWDHARY, B. P., P. D. THOMSEN, I. HARBITZ, M. LANDSET, AND I. GUSTAVSSON. Precise localization of the genes for glucose phosphate isomerase (GPI), calcium release channel (CRC), hormone-sensitive lipase (LIPE) and growth hormone (GH) in pigs using nonradioactive in situ hybridization. Cytogenet. Cell Genet. 67: 211-214, 1994.
64. COLLINS, J. H., A. T. TARCSAFALVI, AND N. IKEMOTO. Identification of a region of calsequestrin that binds to the junctional face membrane of sarcoplasmic reticulum. Biochem. Biophys. Res. Commun 167: 189-193, 1990.
65. CONDRESCU, M., J. R. LOPEZ, P. MEDINA, AND L. ALAMO. Deficient function of the sarcoplasmic reticulum in patients susceptible to malignant hyperthermia. Muscle Nerve 10: 238-241, 1987.
66. 2+ release channel of cardiac sarcoplasmic reticulum by volatile anesthetics. Anesthesiology 81: 459-469, 1994.
67. COOPER, C. C., R. G. CASSENS, AND E. J. BRISKEY. Capillary distribution and fiber characteristics in skeletal muscle of stress susceptible pigs. J. Food Sci. 34: 299-302, 1969.
68. COOPER, P., J. KUDYNSKA, H. A. BUCKMASTER, AND R. KUDYNSKI. An EPR investigation of spin-labelled erythrocytes as a diagnostic technique for malignant hyperthermia. Biochim. Biophys. Acta 1139: 70-76, 1992.
69. COOPER, P., AND J. B. MEDDINGS. Erythrocyte membrane fluidity in malignant hyperthermia Biochim. Biophys. Acta 1069:151-156, 1991.
70. CORONADO, R., J. MORISSETTE, M. SUKHAREVA, AND D. M. VAUGHAN. Structure and function of ryanodine receptors. Am. J. Physiol. 266 (Cell Physiol. 35): C1485-C1504, 1994.
71. DANON, M., G. KARPATI, J. CHARUK, AND P. HOLLAND. Sarcoplasmic reticulum adenosine triphosphatase deficiencies with probable autosomal dominant inheritance. Neurology 38: 812-815,1988.
72. DAVIES, W., I. HARBITZ, R. FRIES, G. STRANZINGER, AND J. G. HAUGE. Porcine malignant hyperthermia carrier detection and chromosomal assignment using a linked probe. Ann. Genet. 19: 203-212, 1988.
73. DENBOROUGH, M. A., X. DENNETT, AND R. M. D. ANDERSON. Central core disease and malignant hyperpyrexia. Lancet 1: 1137-1138, 1973.
74. DENBOROUGH, M. A., J. F. A. FOSTER, R. R. H. LOVTLL D. A. MAPLESTONE, AND J. D. VILLIERS. Anaesthetic deaths in a family. Br. J. Anaesth. 34: 395-396, 1962.
75. DENBOROUGH, M. A., G. J. GALLOWAY, AND K. C. HOPKINSON. Malignant hyperthermia and sudden infant death. Lancet 2: 1068-1069, 1982.
76. DENBOROUGH, M. A., AND R. R. H. LOVELL. Anesthetic deaths in a family. Lancet 2: 45, 1960.
77. 2+ as a second messenger within mitochondria of the heart and other tissues. Annu. Rev. Physiol. 52: 451-466, 1990.
78. DEUFEL, T., M. DOBLER, W. HACKL, AND F. LEHMANN-HORN. Malignant hyperthermia susceptibility (MH): prevalence of the mutation R614C in the ryanodine receptor gene on chromosome 19q13.1 in German and Austrian MH families (Abstract). Am. J. Hum. Genet. 51: A213, 1992.
79. DEUFEL, T., A. GOLLA, D. ILES, A. MEINDL, T. MEITINGER, D. SCHINDELHAUER, A. DEVRIES, D. PONGRATZ, D. H. MACLENNAN, K. J. JOHNSON, AND F. LEHMANN-HORN. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am. J. Hum. Genet. 50: 1151-1161, 1992.
80. DEUFEL, T., W. MULLER-FELBER, D. E. PONGRATZ, G. HUBNER, K. JOHNSON, P. A. IAIZZO, AND F. LEHMANN-HORN. Chronic myopathy in a patient suspected of carrying two malignant hyperthermia susceptibility (MHS) mutations. Neuromuscular Disorders 2: 389-396, 1992.
81. DEUFEL, T., R. SUDBRAK, T. FEIST, B. RUBSAM, I. DUCHESNE, K.-L. SCHAFER, N. ROEWER, T. GRIMM, F. LEHMANN-HORN, E. J. HARTUNG, AND C. R. MULLER. Discordance in a malignant hyperthermia pedigree between in vitro contracture test phenotypes and haplotypes for the MHS1 region on chromosome 19q1213.2 comprising the C1840T transition in the RYR1 gene. Am. J. Hum. Genet. 56: 1334-1342, 1995.
82. DHALLA, N. S., P. V. SULAKHE, N. F. CLINCH, J. G. WADE, AND A. NAIMARK. Influence of fluothane on calcium accumulation by the heavy microsomal fraction of human skeletal muscle: comparison with a patient with malignant hyperpyrexia. Biochem. Med. 6: 333-343, 1972.
83. 2+ release via a TT-SR mechanism. J. Gen. Physiol. 86: 501-525, 1985.
84. 2+ release in normal and malignant hyperthermic muscles. Pfluegers Arch. 414: 15-23, 1989.
85. 2+ release in normal and malignant hyperthermic porcine peeled skeletal muscle fibers (Abstract). Biophys. J. 57: 345a, 1990.
86. DONALDSON, S. K., N. D. GOLDBERG, T. F. WALSETH, AND D. A. HUETTEMAN. Inositol triphosphate stimulates calcium release from peeled skeletal muscle fibers. Biochim. Biophys. Acta 927: 92-99, 1987.
87. DRAPER, D. D., M. F. ROTHSCHILD, D. C. BEITZ, AND L. L. CHRISTIAN. Age- and genotype-dependent differences in the porcine caudate nucleus. Exp. Gerontol. 19: 377-381, 1984.
88. DULHUNTY, A. F., P. R. JUNANKAR, AND C. STANHOPE. Calcium ATPase in the sarcoplasmic reticulum of muscle from normal and malignant hyperthermia susceptible pigs. Neurosci. Lett. 131: 187-192, 1991.
89. DUTHIE, G. G., AND J. R. ARTHUR. The antioxidant abnormality in the stress susceptible pig: the effects of vitamin E supplementation. Ann. NY Acad. Sci. 570: 322-324, 1989.
90. DUTHIE, G. G., AND J. R. ARTHUR. Free radicals and calcium homeostasis: relevance to malignant hyperthermia? Free Radical Biol. Med. 14: 435-442, 1993.
91. DUTHIE. G. G., AND J. R. ARTHUR. Malignant hyperthermia and free radicals. In: Malignant Hyperthermia: A Genetic Membrane Disease, edited by S. T. Ohnishi and T. Ohnishi. Boca Raton, FL: CRC, 1994, p. 152-168.
92. DUTHIE, G. G., J. R ARTHUR, F. NICOL, AND M. J. WALKER. Increased indices of lipid peroxidation in stress susceptible pigs and effects of vitamin E. Res. Vet Sci. 46: 226-230, 1989.
93. DUTHIE, G. G., K. W. J. WAHLE. C. I. HARRIS, J. R. ARTHUR AND P. C. MORRICE. Lipid peroxidation, antioxidant concentrations. d fatty acid contents of muscle tissue from malignant hyperthermia-susceptible swine. Arch. Biochem. Biophys. 296: 592-596, 1992.
94. 2+ release channel of skeletal muscle sarcoplasmic reticulum by palmitoyl carnitine. Biophys. J. 65: 779-789, 1993.
95. EL-HAYAK. R., M. YANO, B. ANTONIU, J. R. MICKELSON, C. F. LOUIS, AND N. IKEMOTO. Altered E-C coupling in triads isolated from malignant hyperthermia-susceptible porcine muscle. Am. J. Physiol. 268 (Cell Physiol. 37): C1381-C1386, 1995.
96. ELIZONDO, G., P. B. ADDIS, W. E. REMPEL, C. MADERO, F. B. MARTIN, D. B. ANDERSON, AND D. N. MARPLE. Stress response and muscle properties in Pietrain (P), Minnesota No. 1 (M) and P x M pigs. J. Anim. Sci. 43: 1004-1014, 1976.
97. ELLIS, F. R., P. J. HALSALL, P. ALLAM, AND E. HAY. A biochemical abnormality found in muscle from unstressed malignant hyperthermia susceptible human. Biochem. Soc. Trans. 12: 357-358, 1984.
98. ELLIS, F. R., P. J. HALSALL, AND D. G. F. HARRIMAN. Malignant hyperpyrexia and sudden infant death syndrome. Br. J. Anaesth. 60: 28-30, 1988.
99. ELLIS, F. R., AND D. G. F. HARRIMAN. A new screening test for susceptibility to malignant hyperpyrexia. Br. J. Anaesth. 45: 638, 1973.
100. ENDO, M., S. YAGI, T. ISHIZUKA, K. HORIUTI, Y. KOGA, AND K. AMAHA. Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient with malignant hyperthermia Biomed. Res. 4: 83-92, 1983.
101. ERVASTI, J. M., M. T. CLAESSENS, J. R. MICKELSON, AND C. F. LOUIS. Altered transverse tubule dihydropyridine receptor binding in malignant hyperthermia. J. Biol. Chem. 264: 2711-2717, 1989.
102. ERVASTI, J. M., J. R. MICKELSON, S. M. LEWIS, D. D. THOMAS, AND C. F. LOUIS. An electron paramagnetic resonance study of skeletal muscle membrane fluidity in malignant hyperthermia. Biochim. Biophys. Acta 986: 70-74, 1989.
103. ERVASTI, J. M., J. R. MICKELSON, AND C. F. LOUIS. Transverse tubule calcium regulation in malignant hyperthermia. Arch. Biochem. Biophys. 269: 497-506, 1989.
104. ERVASTI, J. M., M. A. STRAND, T. P. HANSON, J. R. MICKELSON, AND C. F. LOUIS. Ryanodine receptor in different malignant hyperthermia-susceptible porcine muscles. Am. J. Physiol. 260 (Cell Physiol. 29): C58-C66, 1991.
105. ESSEN-GUSTAVSSON, B., K. KARLSTROM, AND K. LUNDSTROM. Muscle fibre characteristics and metabolic response at slaughter in pigs of different halothane genotypes and their relation to meat quality. Meat Sci. 31: 1-11, 1992.
106. EUROPEAN MALIGNANT HYPERPYREXIA GROUP. A protocol for the investigation of malignant hyperpyrexia. Br. J. Anaesth. 56: 1267-1269, 1984.
107. +-ATPase content in skeletal muscle from malignant hyperthermia patients. Muscle Nerve 14: 162-167, 1992.
108. FAGERLUND, T., G. ISLANDER, E. RANKLEV, I. HARBITZ, J. G. HAUGE, E. MOKLEBY, AND K. BERG. Genetic recombination between malignant hyperthermia and calcium release channel in skeletal muscle. Clin. Genet. 41: 270-272, 1992.
109. FAGERLUND, T., H. ORDING, D. BENDIXEN, AND K. BERG. Search for three known mutations in the RYR1 gene in 48 danish families with malignant hyperthermia. Clin. Genet. 46: 401-404, 1994.
110. FAY, R. S., AND E. M. GALLANT. Halothane sensitivity of young pigs in vivo and in vitro. Am. J. Physiol. 259 (Regulatory Integrative Comp. Physiol. 28): R133-R138, 1990.
111. FENOGLIO, J. J., AND N. S. IREY. Myocardial changes in malignant hyperthermia. Am. J. Pathol. 89: 51-58, 1977.
112. FILL, M., R. CORONADO, J. R MICKELSON, J. VILVEN. J. MA, B. A JACOBSON. AND C. F. LOUIS. Abnormal ryanocdine receptor channels in malignant hyperthermia. Biophys. J. 50: 471-175, 1990.
113. 2+ release channels in malignant hyperthermic skeletal muscle. Biophys. J. 59: 1085-1090, 1991.
114. FINK, H. S., J. G. HOFMANN, H. HENTSCHEL, AND U. TILL. Abnormalities in the regulation of blood platelet free cytosolic calcium in malignant hyperthermia I. Human platelets. Cell Calcium 13: 149-155, 1992.
115. FINK, H. S., J. G. HOFMANN, G. H. VON LENGERKEN, AND U. TILL. Abnormalities in the regulation of blood platelet free cytosolic calcium in malignant hyperthermia. II. Pig platelets. Cell Calcium 13: 157-162, 1992.
116. FTTTS, R. H. Cellular mechanisms of muscle fatigue. Physiol. Rev. 74: 49-94, 1994.
117. FLETCHER, J. E., P. A. CALVO, AND H. ROSENBERG. Phenotypes associated with malignant hyperthermia susceptibility in swine genotyped as homozygous or heterozygous for the ryanodine receptor mutation. Br. J. Anaesth. 71: 410-417, 1993.
118. FLETCHER, J. E., F. J. HUGGINS, AND H. ROSENBERG. The importance of calcium ions for in vitro malignant hyperthermia testing. Can. J. Anaesth. 37: 695-698, 1990.
119. FLETCHER, J. E., S. MAYERBERGER, L. TRIPOLITIS, M. YUDKOWSKY, AND H. ROSENBERG. Fatty acids markedly lower the threshold for halothane-induced calcium release from the terminal cisternae in human and porcine normal and malignant hyperthermia susceptible skeletal muscle. Life Sci. 49: 1651-1657, 1991.
120. FLETCHER, J. E., AND H. ROSENBERG. In vitro muscle contractures induced by halothane and suxamethonium. II. Human skeletal muscle from normal and malignant hyperthermia susceptible patients. Br. J. Anaesth. 58: 1433-1439, 1986.
121. FLETCHER, J. E., H. ROSENBERG, AND K. MICHAUX, Lipid analysis of skeletal muscle from pigs susceptible to malignant hyperthermia. Biochem. Cell Biol. 66: 917-921, 1988.
122. FLETCHER, J. E., H. ROSENBERG, K. MICHAUX, L. TRIPOLITIS, AND F. H. LIZZO. Triglycerides, not phospholipids, are the source of elevated free fatty acids in muscle from patients susceptible to malignant hyperthermia. Eur. J. Anaesthesiol. 6: 355-362, 1989.
123. FLETCHER, J. E., L. TRIPOLITIS, K. ERWIN, S. HANSON, H. ROSENBERG, P. A. CONTI, AND J. BEECH. Fatty acids modulate calcium-induced calcium release from skeletal muscle heavy sarcoplasmic reticulum fractions: implications for malignant hyperthermia. Biochem. Ceil Biol 68: 1195-1201, 1990.
124. FLETCHER, J. E., L. TRIPOLTTIS, H. ROSENBERG, AND J. BEECH. Malignant hyperthermia: halothane- and calcium-induced calcium release in skeletal muscle. Biochem. Mol. Biol. Int. 29: 763-772, 1993.
125. FOSTER, P. S., E. GESINI, C. CLAUDIANOS, K. C. HOPKINSON, AND M. A. DENBOROUGH. Inositol 1,4,5,-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine. Lancet 2: 124-126, 1989.
126. FOSTER, P. S., P. M. HANSBRO, S. P. HOGAN, AND M. DENBOROUGH. Metabolism of inositol polyphosphates by malignant hyperpyrexia-susceptible and control porcine skeletal muscle. In: Malignant Hyperthermia, edited by M. Morio, H. Kikuchi, and O. Yuge. Tokyo: Springer, 1996, p. 107-117.
127. FOSTER, P. S., M. D. WHITE, AND M. A. DENBOROUGH. Characterization of the terminal cisternae and longitudinal tubules of sarcoplasmic reticulum from malignant hyperpyrexia susceptible porcine skeletal muscle. Int. J. Biochem. 21: 1119-1126, 1989.
128. FRANKS, N. P., AND W. R. LIEB. Molecular and cellular mechanisms of general anaesthesia. Nature Land. 367: 607-614, 1994.
129. FRANZINI-ARMSTRONG. C. Studies of the triad: structure of the junction in frog twitch fibers. J. Cell Biol 47: 488-499, 1970.
130. FRENCH, M. W., M. H. RIVNER, P. HARTLAGE, AND T. R. SWIFT. Excitation-contraction time intervals in human malignant hyperthermia. Muscle Nerve 7: 580-581, 1984.
131. 2+ regulation by malignant hyperthermia-susceptible muscle membranes. Anestkesiology 82: 1274-1282, 1995.
132. FRUEN, B. R., J. R. MICKELSON, N. H. SHOMER, T. J. ROGHAIR, AND C. F. LOUIS. Regulation of the sarcoplasmic reticulum ryanodine receptor by inorganic phosphate. J. Biol. Chem. 269: 192-198, 1994.
133. FUJII, J., K. OTSU, F. ZORZATO, S. DE LEON, V. K. KHANNA, J. E. WEILER, P. J. O'BRIEN, AND D. H. MACLENNAN. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science Wash. DC 253: 448-451, 1991.
134. FULCERI, R., A. NORI, A. GAMBERUCCI, P. VOLPE, R. GUNTI, AND A. BENEDETTI. Fatty acyl-CoA esters induce calcium release from terminal cisternae of skeletal muscle. Cell Calcium 15: 109-116, 1994.
135. 2+ release channels are differentially expressed in rabbit brain. J. Neurosci. 14: 4794-4805, 1994.
136. GALLANT, E. M. Porcine skeletal muscle for physiological studies. Experientia Basel, 35: 790, 1979.
137. GALLANT, E. M. Histochemical observations on muscle from normal and malignant hyperthermia-susceptible swine. Am. J Vet Med. 41: 1069-1071, 1980.
138. GALLANT, E. M. Porcine malignant hyperthermia: no role for plasmalemmal depolarization. Muscle Nerve 11: 785-786, 1988.
139. GALLANT, E. M., E. BALOG, AND K. G. BEAM. Slow calcium current is not reduced in malignant hyperthermic (MH) porcine myotubes. Muscle Nerve, In press.
140. GALLANT, E. M., AND S. K. DONALDSON. Skeletal muscle excitation-contraction coupling. II. Plasmalemma voltage control of intact bundle contractile properties in normal and malignant hyperthermic muscles. Pfluegers Arch. 414: 24-30, 1989.
141. GALLANT, E. M., T. F. FLETCHER, V. M. GOETTL, AND W. E. REMPEL. Porcine malignant hyperthermia: cell injury enhances halothane sensitivity of biopsies. Muscle Nerve. 9:174-184, 1986.
142. GALLANT, E. M., F. F. FOLDES, W. E. REMPEL, AND G. A. GRONERT. Verapamil is not a therapeutic adjunct to dantrolene in porcine malignant hyperthermia. Anesth. Analg. 64: 601-606, 1985.
143. GALLANT, E. M., R. E. GODT, AND G. A. GRONERT. Role of plasma membrane defect of skeletal muscle in malignant hyperthermia. Muscle Nerve 2: 491-494, 1979.
144. GALLANT, E. M., R. E. GODT, AND G. A. GRONERT. Mechanical properties of normal and malignant hyperthermia susceptible porcine muscle: effects of halothane and other drugs. J. Pharmacol. Exp. Ther. 213: 91-96, 1980.
145. GALLANT, E. M., AND V. M. GOETTL. Porcine malignant hyperthermia; halothane effects on force generation in skeletal muscles. Muscle Nerve 12: 56-63, 1989.
146. GALLANT, E. M., G. A. GRONERT, AND S. R. TAYLOR. Cellular membrane potential and contracture threshold in mammalian skeletal muscle susceptible to malignant hyperthermia. Neurosci Lett. 28: 181-186, 1982.
147. GALLANT, E. M., AND R. C. JORDAN. Porcine malignant hyperthermia: genotype and contractile threshold of immature muscles. Muscle Nerve. 19: 68-73, 1996.
148. GALLANT, E. M., AND L. R. LENTZ. Excitation-contraction coupling in pigs heterozygous for malignant hyperthermia. Am. J. Physiol 262 (Cell Physiol 31): C422-C426, 1992.
149. GALLANT, E. M., J. R. MICKELSON, B. D. ROGGOW, S. K. DONALDSON, C. F. LOUIS, AND W. E. REMPEL. Halothane-sensitivity gene and muscle contractile properties in malignant hyperthermia, Am. J. Physiol. 257 (Cell Physiol. 26): C781-C786, 1989.
150. 2+ channel that is regulated by TGF-β. Science Wash. DC 257: 91-94, 1992
151. GIANNINI, G., A. COOTI, S. MAMMARELLA, M. SCROBOGNA, AND V. SORRENTINO. The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J. Cell Biol. 128: 893-904, 1995.
152. GILLARD, E. F, K OTSU, J. FUJII, C. DUFF, S. DE LEON, V. K. KHANNA, B. A. BRITT, R. G. WORTON, AND D. H. MACLENNAN. Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 13: 1247-1254, 1992.
153. GILLARD, E. F, K. OTSU, J. FUJII, V. K. KHANNA, S. DE LEON. J. DERDEMEZI, B. A. BRITT, C. L. DUFF, R. G. WORTON, AND D. H. MACLENNAN. A substitution of cysteine for arginine 614 in e ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 11: 751-755, 1991.
154. GORDON, R. A., B. A. BRITT, AND W. KALLOW. International Symposium on Malignant Hyperthermia. Springfield, IL: Thomas, 1973, p. 1-489.
155. GREASER, M. L., R. G. CASSENS, E. J. BRISKEY, AND W. G. HOEKSTRA. Post-mortem changes in subcellular fractions from normal and pale, soft, exudative porcine muscle. I. Calcium accumulation and adenosine triphosphatase activities. J. Food Sci. 34: 120-124, 1969.
156. GREASER, M. L., R. G. CASSENS, E. J. BRISKEY, AND W. G. HOEKSTRA. Post-mortem changes in subcellular fractions from normal and pale, soft, exudative porcine muscle. II. Electron microscopy. J. Food Sci. 34: 125-132, 1969.
157. GREASER, M. L., R. G. CASSENS, AND W. G. HOEKSTRA. Changes in oxalate-stimulated calcium accumulation in paroculate fractions from post-mortem muscle, J. Agric. Food Chem. 15: 1112-1117, 1967.
158. GREASER, M. L., R. G. CASSENS, W. G. HOEKSTRA, AND E. J. BRISKEY. The effect of pH-temperature treatments on the calciumaccumulating ability of purified sarcoplasmic reticulum. J. Food Sci. 34: 633-637, 1969.
159. GRONERT, G. A. Malignant hyperthermia. Anesthesiology 53: 395-423, 1980.
160. GRONERT, G. A. Malignant hyperthermia. In: Myology, edited by A. G. Engel and B. Q. Banker. New York: McGraw Hill, 1986, p. 1763-1784.
161. GRONERT, G. A. Myology, edited by A. G. Engel and C. FranziniArmstrong. New York: McGraw-Hill, 1994, p. 1661-1668.
162. GRONERT, G. A., C. P. AHERN, AND J. H. MILDE. Treatment of porcine malignant hyperthermia: lactate gradient from muscle to blood. Can. Anaesth. Soc. J. 33: 729-736, 1986.
163. 2, calcium, digoxin, and potassium on cardiac and skeletal muscle metabolism in malignant hyperthermia susceptible swine. Anesthesiology 64: 24-28, 1986.
164. GRONERT, G. A., AND J. F. ANTOGNINI. Malignant hyperthermia. In: Anesthesia, edited by R. D. Miller. New York: Churchill Livingstone, 1994, p. 1075-1093.
165. GRONERT, G. A., J. J. A. HEFFRON, AND S. R. TAYLOR. Skeletal muscle sarcoplasmic reticulum in porcine malignant hyperthermia. Eur. J. Pharmacol. 58: 179-187, 1979.
166. GRONERT, G. A., J. H. MILDE, AND R. A THEYE. Role of sympathetic activity in porcine malignant hyperthermia. Anesthesiology 47: 411-415, 1977.
167. GRONERT, G. A, AND R. A. THEYE. Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes. Anesthesiology 44: 36-43, 1976.
168. GRONERT, G. A., R. A. THEYE, J. H. MILDE, AND J. H. TINKER. Catecholamine stimulation of myocardial oxygen consumption in porcine malignant hyperthermia. Anesthesiology 49: 330-337, 1978.
169. GRONERT, G. A., R. L. THOMPSON, AND B. M. ONOFRIO. Human malignant hyperthermia: awake episodes and correction by dantrolene. Anesth. Analg. 59: 377-378, 1980.
170. GRUENER, R., AND T. BLANCK Volatile anesthetics and skeletal muscle: evidence for sarcolemmal involvement in malignant hyperthermia. In: Molecular Mechanisms of Anesthesia. Progress in Anesthesiology, edited by B. R. Fink. New York: Raven, 1980, vol. 2, p. 423-427.
171. GUNTER, K. K., AND T. E. GUNTER. Transport of calcium by mitochondria. J. Bioenerg. Biomembr. 26: 471-485, 1994.
172. GUO, W., AND K. P. CAMPBELL. Association of triadin with the ryanodine receptor and calsequestrin in the lumen of the sarcoplasmic reticulum. J. Biol. Chem. 270: 9027-9030, 1995.
173. HAGGENDAHL, J., L. JONSSON, AND J. CARSTEN. The role of sympathetic activity in initiating malignant hyperthermia. Acta Anaesth. Scand. 38: 677-682, 1990.
174. HAGGENDAHL, J., L. JONSSON, G. JOHANSSON, S. BJURSTOM, AND J. CALSTEN. Disordered catecholamine release in pigs susceptible to malignant hyperthermia.
175. HAKAMATA. Y., J. NAKAI, H. TAKESHIMA, AND K. IMOTO. Primary ructure and distribution of a novel ryanodine receptor/calcium release channel from rabbit brain. Fed. Eur. Biochem. Soc. Lett, 312: 229-235, 1992.
176. HALL, G. M., AND J. N. LUCKE. Porcine malignant hyperthermiaIX. Changes in the concentrations of intramuscular high-energy phosphates, glycogen, and glycolytic intermediates. Br. J. Anaesth. 55: 635-640, 1983.
177. HALL, L. W., M. WOOLF, J. W. BRADLEY, AND D. W. JOLLY. Unusual reaction to suxamethonium chloride. Br. Med. J. 2: 1305, 1966.
178. HALL-CURRAN, J. L., A. D. STEWART, S. P. BALL, J. P. HALSALL, P. M. HOPKINS, AND F. R. ELLIS. No C1840 to T mutation in RYR1 in malignant hyperthermia. Hum. Mutation 2: 330, 1993.
179. HALSALL, P. J., F. R. ELLIS, AND P. F. KNOWLES. Evaluation of spin resonance spectroscopy of red blood cell membranes to detect malignant hyperthermia susceptibility. Br. J. Anaesth. 69: 471-473, 1992.
180. 2+ release can result from depolarization of T-tubules. J. Muscle Res. Cell Motil. 13: 447-456, 1992.
181. HARBITZ, I., B. CHOWDARY, P. D. THOMSEN, W. DAVIES, U. KAUFMANN, S. KRAN, I. GUSTAVSSON, K. CHRISTENSEN, AND J. G. HAUGE. Assignment of the porcine calcium release channel gene, a candidate for the malignant hyperthermia locus, to the 6p11 q21 segment of chromosome 6. Genomics 8: 243-248, 1990.
182. HARBITZ, I., T. KRISTENSEN, M. BOSNES, S. KRAN, AND W. DAVIES. DNA sequence of the skeletal muscle calcium release channel cDNA and verification of the Arg615Cys615 mutation, associated with porcine malignant hyperthermia, in Norwegian Landrace pigs. Ann. Genet. 23: 395-402, 1992.
183. HARRIMAN, D. G. F. Malignant hyperthermia myopathy: a critical review. Br. J. Anaesth. 60: 309-316, 1988.
184. HARRISON, C. G. Porcine malignant hyperthermia. Br. Int. Anesth. Clin. 17: 25-61, 1979.
185. HARRISON, G. G., J. F. BIEBUYCK, J. TERBLANCHE, D. M. DENT, R. HICKMAN, AND S. J. SAUNDERS. Hyperpyrexia during anaesthesia. Br. Med. J. 3: 594-595, 1968.
186. HARRISON, G. G., AND C. VERBURG. Erythrocyte osmotic fragility in hyperthermia susceptible swine. Br. J. Anaesth. 45: 131-133, 1973.
187. 2+-release channel in malignant hyperthermia. J. Biol. Chem. 267: 6702-6709, 1992.
188. HEALY, J. M. S , J. J. A. HEFFRON, M. LEHANE, D. G. BRADLEY, K. JOHNSON, AND T. V. MCCARTHY. Diagnosis of susceptibility to malignant hyperthermia with flanking DNA markers. Br. Med. J. 303: 1225-1228, 1991.
189. HEFFRON, J. J. A., AND H. ISAACS. Malignant hyperthermia syndrome: evidence for denervation changes in human skeletal muscle. Klin. Wochenschr. 54: 865-867, 1976.
190. HEIMAN-PATTERSON, T., J. E. FLETCHER, H. ROSENBERG, AND A. J. TAHMOUSH. No relationship between fiber type and halothane contracture test results in malignant hyperthermia. Anesthesiology 67: 82-84, 1987.
191. HEIMAN-PATTERSON, T. D., H. ROSENBERG, J. E. FLETCHER, AND A. J. TAHMOUSH. Halothane-caffeine contracture testing in neuromuscular diseases. Muscle Nerve. 11: 453-457, 1988.
192. HERRMANN-FRANK, A., M. RICHTER, S. SARKÖZI, U. MOHR, AND F. LEHMANN-HORN. 4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim. Biophys. Acta. In press.
193. HOFFMAN, E. P., F. LEHMAN-HORN, AND R. RUDEL. Over excited or inactive: ion channels in muscle disease Cell 80: 681-686, 1995.
194. HOGAN. K., F. COUCH, P. A. POWERS, AND R. G. GREGG. A cysteine-for-arginine substitution (R614C) in the human skeletal muscle calcium release channel cosegregates with malignant hyperthermia. Anesth. Analg. 75: 441-448, 1992.
195. HOPKINS, P M., F. R. ELLIS, AND P. J. HALSALL. Ryanodme contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br. J. Anaesth. 66: 611-613, 1991.
196. HOPKINS, P. M., F. R. ELLIS, AND P. J. HALSALL. Inconsistency of data linking the ryanodine receptor and malignant hyperthermia genes. Anesthesiology 76: 659-660, 1992.
197. HOPKINS, P. M., F. R. ELLIS, AND P. J. HALSALL Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders. Br. J. Anaesth. 70: 397-401, 1993.
198. HUCKELL, V. F., H. M. STANILOFF, B. A. BRITT, AND J. E. MORCH. Electrocardio-graphic abnormalities associated with malignant hyperthermia susceptibility. J. Electrocardiol. 15: 137-142, 1982.
199. HUCKELL, V. F, H. M. STANILOFF, B. A. BRITT, M. B. WAXMAN, AND J. E. MORCH. Cardiac manifestations of malignant hyperthermia susceptibility. Circulation 58: 916-925, 1980.
200. HULL, M. T., J. MULLER, AND W. H. ALBRECHT. Morphologic abnormalities in a case of malignant hyperthermia Anesthesiology 48: 223-228, 1978.
201. IAIZZO, P. A., F. LEHMANN-HORN, S. R. TAYLOR, AND E. M. GALLANT. Malignant hyperthermia: effects of halothane on the surface membrane. Muscle Nerve 12: 178-183, 1989.
202. IAIZZO, P. A., W. KLEIN, AND F. LEHMANN-HORN. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pfluegers Arch. 411: 648-653, 1988.
203. 2+] in human skeletal muscle. Cell Calcium 10: 151-158, 1989.
204. 2+ induced by halothane in hepatocytes isolated from swine susceptible to malignant hyperthermia. Anesthesiology 74: 531-538, 1991.
205. 2+ release from sarcoplasmic reticulum. Biochemistry 28: 6764-6771, 1993.
206. ILES, D. E., F. LEHMANN-HORN, S. W. SCHERER, L-C. TSUI, D. O. WEGHUIS, R. F. SUIJKERBUIJK, L HEYTENS, G. MIKALA, A. SCHWARTZ, F. R. ELLIS, A. D. STEWART, T. DEUFEL, AND B. WIERINGA Localization of the gene encoding the α2/δ-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum. Mol. Genet. 3: 969-975, 1994.
207. ILES, D. E, B. SEGERS, L. HEYTENS, R. C. A. SENGERS, AND B. WIERINGA High-resolution physical mapping of four microsatellite repeat markers near the RYR1 locus on chromosome 19q13.1 and apparent exclusion of the MHS locus from this region in two malignant hyperthermia susceptible families. Genomics 14: 749-754, 1992.
208. ILES, D. E., B. SEGERS, R. C. A SENGERS, K. MONSIEURS, L. HEYTENS, P. J. HALSALL, P. M. HOPKINS, F. R. ELLIS, J. L HALL CURRAN, A. D. STEWART, AND B. WIERINGA Genetic mapping of the β1- and y-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility. Hum. Mol Genet. 2: 863-868, 1993.
209. ILIAS, W. K., C. H, WILLIAMS, R. T. FULFER, AND S. E. DOZIER. Diltiazem inhibits halothane-induced contractions in malignant hyperthermia-susceptible muscles in vitro. Br. J. Anaesth. 57: 994-996, 1985.
210. INUI, M, A. SAITO, AND S. FLEISCHER. Purification of the ryanodine receptor and identity with feet structures of junctional terminal cisternae of sarcoplasmic reticulum from fast skeletal muscle. J. Biol. Chem. 262: 1740-1747, 1987.
211. ISAACS, H. L, AND M. BADENHORST. False negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 79: 5-9, 1993.
212. ISAACS, H., G. FRERE, AND J. MITCHELL. Histology, histochemical and ultramicroscopic findings in muscle biopsies from carriers of the trait malignant hyperpyrexia. Br. J. Anaesth. 45: 860-868, 1973
213. ISAACS, H., AND J. J. A. HEFFRON. Morphological and biochemical defects in muscles of human carriers of the malignant hyperthermia syndrome. Br. J. Anaesth. 47: 475-481, 1975.
214. ISAACS, H., J. J. A. HEFFRON, AND M. BADENHORST. Predictive tests for malignant hyperpyrexia. Br. J. Anaesth. 47: 1075-1079, 1975.
215. ISLANDER, G., K.-G. HENRIKSSON, AND E. RANKLEV-TWETMAN. Malignant hyperthermia susceptibility without central core disease (CCD) in a family where CCD is diagnosed. Neuromuscular Disorders 5: 125-127, 1995.
216. JAYARAMAN, T., A.-M. BRILLANTES, A. P. TIMERMAN, H. ERDJUMENT-BROMAGE, S. FLEISCHER, P. TEMPST, AND A. E. MARKS. PK506-binding protein associated with the calcium release channel (ryanodine receptor). J. Biol. Chem. 268: 25385-25388, 1993.
217. JENSEN, P., AND P. BARTON-GADE. Performance and carcass characteristics of pigs with known genotypes forhalothane susceptibility. Eur. Assoc. Anim. Prod. Pub. 33: 80-87, 1985.
218. JOFFE, M., N. SAVAGE, AND M. SILOVE. The biochemistry of malignant hyperthermia: recent concepts. Int. J. Biochem. 24: 387-398, 1992.
219. JOHNSON, K. Malignant hyperthermia hots up! Hum. Mol. Genet. 2: 849, 1993.
220. JURKAT-ROTT, K, F. LEHMAN-HORN, A. ELBAZ, R. HEINE, R. G. GREGG, K HOGAN, P. POWERS, P. LAPIE, J. E. VALE-SANTOS, J. WEISSENBACH, AND B. FONTAINE. A calcium channel mutation causing hypokalemic periodic paralysis. Hum. Mol. Genet. 3: 1415-1419, 1994.
221. KAIDO, M., K. ARAHATA, E. P. HOFFMAN, I. NONAKA, AND H. SUGITA Muscle histology in Becker muscular dystrophy. Muscle Nerve 14: 1067-1073, 1991.
222. KALOW, W., B. A. BRITT, AND F.-Y. CHAN. Epidemiology and inheritance of malignant hyperthermia. Int. Anesthesiol. Clin., 17: 119-139, 1979.
223. KALOW, W., B. A. BRITT, M. E. TERREAU, AND C. HAIST. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 2: 895-898, 1970.
224. 2+-adenosine triphosphatase in sarcoplasmic reticulum (Brody's disease). Ann. Neural. 20: 38-49, 1986.
225. KAUSCH, K, F. LEHMANN-HORN, M. JANKA, B. WIERINGS, T. GRIMM, AND C. R. MILLER. Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19. Genomics 10: 765-769, 1991.
226. KAWAMOTO, R. M., J. P. BRUNSCHWIG, K. C. KIM, AND A H. CASWELL. Isolation, characterization, and localization of the spanning protein from skeletal muscle triads. J. Cell Biol. 103: 1405-1414, 1986.
227. KAWANA, Y., M. IINO, K. HORIUTI, N. MATSUMURA, T. OHTA, K. MATSUI, AND M. ENDO. Acceleration in calcium-induced calcium release in the biopsied muscle fibers from patients with malignant hyperthermia. Biomed. Res. 13: 287-297, 1992.
228. KAWASAKI, T., AND M. KASAI. Regulation of calcium channel in sarcoplasmic reticulum by calsequestrin. Biochem. Biophys Res. Commun. 199: 112-117, 1994.
229. KEATING, K. E., K. A. QUANE, B. M. MANNING, M. LEHANE, E HARTUNG, K. CENSIER, A. URWYLER, M. KLAUSNITZER, C. R. MULLER, J. J. A. HEFFRON, AND T. V. MCCARTHY. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum. Mol. Genet. 3: 1855-1858, 1994.
230. KERR, D. D., D. W. WINGARD, AND E. E. GATZ. Prevention of porcine MH by epidural block. Anesthesiology 42: 307-311, 1975.
231. 2+ release from sarcoplasmic reticulum of normal and malignant hyperthermia susceptible pig muscles. Biochim. Biophys. Acta 775: 320-327, 1984.
232. KIM, K., A. H. CASWELL, J. A. TALVENHEIMO, AND N. R. BRANDT. Isolation of a terminal cisterna protein which may link the dihydropyridine receptor to the junctional foot protein in skeletal muscle. Biochemistry 29: 9281-9289, 1990.
233. KISTLER, P., J. E. FLETCHER, AND H. ROSENBERG. Erythrocyte fragility screening is not a tool for diagnosis of human malignant hyperthermia. Anesth. Analg. 66: 1004-1007, 1987.
234. KLIMANEK, J., W. MAJEWSKI, AND K. WALENCIK. A case of MH during epidural analgesia. Anaesth. Resusc. 4: 143-146, 1976.
235. 2+ in blood cells in malignant hyperthermia. Am. J. Physiol. 258 (Cell Physiol. 27): C495-C503, 1990.
236. KLIP, A., T. RAMTAL, D. WALKER, B. A. BRITT, AND M. E. ELLIOTT. Selective increase in cytoplasmic calcium by anesthetic in lymphocytes from malignant hyperthermia susceptible pigs. Anesth. Analg. 66: 381-385, 1987.
237. 2+ release channel in malignant hyperthermia. J. Biol. Chem. 265: 2421-2424, 1990.
238. KNUDSON, C. M., KL K STANG, A. O. JORGENSEN, AND K. P. CAMPBELL. Biochemical characterization and ultrastructural localization of a major junctional sarcoplasmic reticulum glycoprotein (triadin). J. Biol. Chem. 268: 12637-12645, 1993.
239. KNUDSON, C. M., K. K STANG, C. R. MOOMAW, C. A. SLAUGHTER, AND K. P. CAMPBELL. Primary structure and topologographical analysis of a skeletal muscle-specific junctional sarcoplasmic reticulum glycoprotein (triadin). J. Biol. Chem. 268: 12646-12654, 1993.
240. KOCHS, E., W. E. HOFFMAN, N. ROEWER, AND J. SCHULTE AM ESCH. Alterations in brain electrical activity may indicate the onset of malignant hyperthermia in swine. Anesthesiology 73: 1236-1242, 1990.
241. KOCHS, E., W. E. HOFFMAN, AND J. SCHULTE AM ESCH. Improvement of brain electrical activity during treatment of porcine malignant hyperthermia with dantrolene. Br. J. Anaesth 71: 881-884, 1993.
242. 31P NMR. Arch. Biochem. Biophys. 287: 312-319, 1991.
243. KRIVOSIC-HORBER, R., H. REYFORT, M. C. BECQ, AND P. ADNET. Effect of propofol on the malignant hyperthermia susceptible pig model. Br. J. Anaesth. 62: 691-693, 1989.
244. LAI, F. A., H. P. ERICKSON, E. ROUSSEAU, Q. Y. LIU, AND G. MEISSNER. Purification and reconstitution of the calcium release channel from skeletal muscle. Nature Lond. 331: 315-319, 1988.
245. 2+] in normal and mutant myotubes (Abstract). Biophys. J 68: A175, 1995.
246. 2+ inhibition and malignant hyperthermia. J. Muscle Res. Cell Motil. 14: 554-556, 1993.
247. LAMB, G. D., K. C. HOPKINSON, AND M. A. DENBOROUGH. Calcium currents and asymmetric charge movement in malignant hyperpyrexia. Muscle Nerve 12: 135-140, 1989.
248. 247a.LAMBERT, C., Y. BLANOCIL, R. KRIVOSIC HORBER, L. BERNARD, H. REYFORD, AND M. PINAUD. Malignant hyperthermia in a patient with hypokalemic periodic paralysis. Anesth. Analg. 79: 1012-1014, 1994.
249. LARACH, M. G. Standardization of the caffeine halothane muscle contracture test. Anesth. Analg. 69: 511-515, 1989.
250. LARACH, M. G. Should we use muscle biopsy to diagnose malignant hyperthermia susceptibility. Anesthesiology 79: 1-4, 1993.
251. LARACH, M. G., J. R. LANDIS, J. S. BUNN, .AND M. DIAZ. The North American Registry. Prediction of malignant hyperthermia susceptibility in low-risk subjects. Anesthesiology 76: 16-27, 1992.
252. LARACH, M. G., ET AL A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 80: 771-779, 1994.
253. 2+channel is expressed in nonexcitable cells. Mol. Pharmacol. 47: 21-28, 1995.
254. LEDBETTER, M. W., J. K. FREINER, C. F. LOUIS, AND J. R. MICKELSON. Tissue distribution of ryanodine receptor isoforms and alleles determined by reverse transcription polymerase chain reaction. J. Biol. Chem. 269: 31544-31551, 1994.
255. LEHMANN-HORN, F., AND P. A. IAIZZO. Are myotonias and periodic paralysis associated with susceptibility to malignant hyperthermia? Br. J. Anaesth. 65: 692-697, 1990.
256. LENNMARKEN, D., H. RUBERG, AND K. G. HENRIKSSON. Abnormal relaxation rates in subjects susceptible to malignant hyperthermia. Acta Neurol. Scand. 75: 81-83, 1987.
257. LENZEN, C., N. ROEWER, F. WAPPLER, J. SCHOLZ, J. KAHL, M. BLANK, E. RUMBERGER, AND J. SCHLTLTE AM ESCH. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients. Br. J. Anaesth. 71: 242-246, 1993.
258. LEVTTT, R. C., N. NOURI, A. E. JEDLICKA, V. A. McKUSICK, A. R. MARKS, J. G. SHUTACK, J. E. FLETCHER, H. ROSENBERG, AND D. A. MEYERS. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 11: 543-547, 1991.
259. LEVITT, R. C., A. OLCKERS, S. MEYERS, J. E. FLETCHER, H. ROSENBERG, H. ISAACS, AND D. A. MEYERS. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 14: 562-566, 1992.
260. LOPEZ, J. R., L ALAMO, C. CAPUTO, J. WIKINSKI, AND D. LEDEZMA. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve 8: 355-358, 1985.
261. 2+ selective microelectrodes. Muscle Nerve 9: 85-86 1986.
262. 2+] during a malignant hyperthermia episode in swine. Muscle Nerve 11: 82-88, 1988.
263. LOPEZ, J. R., P. ALLEN, L. ALAMO, J. F. RYAN, D. E. JONES, AND F. SRETER. Dantrolene prevents the malignant hyperthermic syndrome by reducing free intracellular calcium concentration in skeletal muscle of susceptible swine. Cell Calcium 8: 385-396, 1987.
264. 2+] measured in vivo in patients susceptible to malignant hyperthermia Anesthesiology 76: 711-719, 1992.
265. 2+], produced by microinjection of inositol (1,4,5) trisphosphate in swine skeletal muscle (Abstract). Biophys. J. 57: 173a, 1990.
266. 2+], in muscle from humans with malignant hyperthermia. Muscle Nerve 10: 77-79, 1987.
267. 2+] in malignant hyperthermia susceptible swine. Anesthesiology 73: 109-117, 1990.
268. 267a.LOPEZ-PADRINO, J. R. Free calcium concentration in skeletal muscle of malignant hyperthermia susceptible subjects: effects of ryanodine. In: Malignant Hyperthermia: A Genetic Membrane Disease, edited by S. T. Ohnishi and T. Ohnishi. Boca Raton, FL: CRC, 1994 p. 133-150.
269. LOUIS, C. F., T. ROGHAIR, AND J. R. MICKELSON. Volatile anesthetics inhibit dihydropyridine binding to malignant hyperthermia-susceptible and normal pig skeletal muscle membranes. Anesthesiology 80: 618-624, 1994.
270. LOUIS, C. F., K. ZUALKERNAN, T ROGHAIR, AND J. R. MICKELSON. The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 77: 114-125, 1992.
271. LUCKE, J. N , G. M. HALL, AND D. LISTER. Porcine malignant hyperthermia. I. Metabolic and physiological changes. Br. J. Anaesth. 48: 297-304, 1976.
272. LUFF, A, R , AND H. L WOOD. Changes in the sarcoplasmic reticulum and transverse tubule system of fast and slow lateral muscles of the mouse during postnatal development. J. Cell Biol. 51: 369-383, 1971.
273. MABRY, J. W., L.L. CHRISTIAN. AND D. L. KUHLERS. Inheritance of porcine stress syndrome. J. Hered. 72: 429-430, 1981.
274. 2-uptake by sarcoplasmic reticulum. Anal. Biochem. 86: 733-742, 1978.
275. MACKENZIE, A. E., G. ALLEN, D. LAHEY, M.-L. CROSSAN, K. NOLAN, G. METTLER, R. G. WORTON, D. H. MACLENNAN, AND R. KORNELUK. A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia. Anesthesiology 73: 4-8, 1991.
276. MACKENZIE, A. J., K. G. COUCHMAN, AND N. POLLOCK. Propofol is a safe anesthetic agent in malignant hyperthermia susceptible patients. Anaesth. Intensive Care 20: 165-168, 1992.
277. MACKENZIE, A. E., R. G. KORNELUK, F. ZORZATO, J. FUJII, M. PHILLIPS, D. ILES, B. WIERINGA, S. LEBLOND, J. BAILLY, H. F. WILLARD, C. DUFF, R. G. WORTON, AND D. H. MACLENNAN. The human ryanodine receptor gene: its mapping to 19q13.1, placement in a chromosome 19 linkage group, and exclusion as the gene causing myotonic dystrophy. Am. J. Hum. Genet. 46: 1082-1089, 1990.
278. MACKENZIE, A., AND D. H. MACLENNAN. Reply Anesthesiology 76: 660-661, 1992.
279. 2+-ATPase genes map to human chromosomes 16 and 12. Somatic Cell Mol. Genet. 13: 341-346, 1987.
280. MACLENNAN, D. H., C. DUFF, F. ZORZATO, J. FUJII, M. PHILLIPS, R. G. KORNELUK, W. FRODIS, B. A. BRITT, AND R. G. WORTON. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature Land. 343: 559-561, 1990.
281. MACLENNAN, D. H., AND M. S. PHILLIPS. Malignant hyperthermia. Science Wash. DC 256: 789-794, 1992.
282. MACLENNAN, D. H., AND M. S. PHILLIPS. The role of the RYR1 gene in malignant hyperthermia and central core disease. In: Ion Channels and Genetic Diseases, edited by D. C. Dawson and R. A Frizzell. New York: Rockefeller Univ. Press, 1995.
283. MACLENNAN, D. H., AND M. S. PHILLIPS. The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia and central core disease. In: Ryanodine Receptors, edited by V. Sorrentino. Boca Raton, FL: CRC, 1995.
284. MACLENNAN, D. H., M. S. PHILLIPS, AND Y. ZHANG. The genetic and physiological basis of malignant hyperthermia. In: Molecular Biology and Membrane Biology of Membrane Transport Disorders, edited by S. G. Schultz, T. E. Andreoli, A. M. Brown, D. Fambrough, J. Hoffman, and M. J. Welsh. New York: Plenum, 1995.
285. MAMBO, N. C., M. D. SILVER, P. R. McLAUGHLIN, V. F. HUCKELL, P. M. McEWAN, B. A. BRITT, AND J. E. MORCH. Malignant hyperthermia susceptibility. A light and electron microscopic study of endomyocardial biopsy specimens from nine patients. Hum. Pathol. 11: 381-388, 1980.
286. McCARTHY, T. V., J. M. S. HEALY, J. J. A. HEFFRON, M. LEHANE, T. DEUFEL, F. LEHMANN-HORN, M. FARRALL, AND K. JOHNSON. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature Lond. 343: 562-564, 1990.
287. McINTOSH, D. B., M. C. BERMAN, AND J. E. KENCH. Characteristics of sarcoplasmic reticulum from slowly glycolysing and from rapidly glycolysing pig skeletal muscle post mortem. Biochem. J. 166: 387-398, 1977.
288. 2+ release channel. J. Biol. Chem. 268: 19785-19790, 1993.
289. McSWEENEY, D. M., AND J. J. A. HEFFRON. Uptake and release of calcium ions by heavy sarcoplasmic reticulum fraction of normal and malignant hyperthermia-susceptible human skeletal muscle. Int. J. Biochem. 22: 329-333, 1990.
290. 2+ release channel of sarcoplasmic reticulum. J. Biol. Chem. 261: 6300-6306, 1986.
291. 2+ release channels and their regulation by endogenous effectors. Annu. Rev. Physiol. 56: 485-508, 1994.
292. 2+, and adenine nucleotides. Biochemistry 25: 236-244, 1986.
293. 2+ release channel of skeletal and cardiac sarcoplasmic reticulum. Mol. Cell. Biochem. 82: 59-65, 1988.
294. MELTON, A. T., R. W. MARTUCCI, N. D. MEN, AND G. A. GRONERT. Malignant hyperthermia in humans - standardization of contracture testing protocol. Anesth. Analg. 69: 437-443, 1989
295. 2+ ions in excitation-contraction coupling of skeletal muscle fibers. Biochim. Biophys. Acta 1241: 59-116, 1995.
296. MICKELSON, J. R., J. M. ERVASTI, L A. LITTERER, K. P. CAMPBELL, AND C. F. LOUIS. Skeletal muscle junctional membrane protein content in pigs with different ryanodine receptor genotypes. Am. J. Physiol. 267 (Cell Physiol 36): C282-C292, 1994.
297. MICKELSON, J. R., E. M. GALLANT, L. A. LITTERER, K. M. JOHNSON, W. E. REMPEL, AND C. F. LOUIS. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia J. Biol Chem. 263: 9310-9315, 1988.
298. MICKELSON, J. R., E. M. GALLANT, W. E. REMPEL, K. M. JOHNSON, L. A. LITTERER, B. A. JACOBSON, AND C. F. LOUIS. Effects of the halothane-sensitivity gene on sarcoplasmic reticulum function. Am. J. Physiol. 257 (Cell. Physiol. 26): C787-C784, 1989.
299. MICKELSON, J. R., C. M. KNUDSON, C. F. H. KENNEDY, D.-L YANG, L. A. LITTERER, W. E. REMPEL, K. P. CAMPBELL, AND C. F. LOUIS. Structural and functional correlates of a mutation in the malignant hyperthermia-susceptible pig ryanodine receptor. Fed. Eur. Biochem. Soc. Lett. 301: 49-52, 1992.
300. 3H]ryanodine binding to sarcoplasmic reticulum from malignant hyperthermia susceptible pigs. Arch. Biochem. Biophys. 278: 251-257, 1990.
301. MICKELSON, J. R., J. A. ROSS, R. J. HYSLOP, E. M. GALLANT, AND C. F. LOUIS. Skeletal muscle sarcolemma in malignant hyperthermia: evidence for a defect in calcium regulation. Biochim. Biophys. Acta 897: 364-376, 1987.
302. 2+-induced calcium release by isolated sarcoplasmic reticulum vesicles from malignant hypeithermia susceptible pig muscle. Biochim. Biophys. Acta 862: 318-328, 1986.
303. MICKELSON, J. R., H. S. THATTE, T. M. BEAUDRY, E. M. GALLANT, AND C. F. LOUIS. Increased skeletal muscle acetylcholinesterase activity in porcine malignant hyperthermia, Muscle Nerve 10: 723-727, 1987.
304. 1. Biophys. J. 65: 561-562, 1993.
305. MORONI, I., E. F. GONANO, G. P. COMI, V. TEGAZZIN, A. PRELLE, A. BORDONI, N. BRESOLIN, AND G. SCARLATO. Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility. J. Neurol. 242: 127-133, 1995.
306. 2+ from permeabilized cardiac myocytes and sarcoplasmic reticulum. Fed. Eur. Biochem. Soc. Lett. 185: 328-332, 1985.
307. MULLEY, J. C., H. M. KOZMAN, H. A. PHILLIPS, A. K. GEDEON, J. A. McCURE, D. E. ILES, R. G. GREGG, K. HOGAN, F J. COUCH, D. H. MACLENNAN, AND E. A. HAAN. Refined genetic localization for central core disease. Am. J. Hum. Genet 52: 398-405, 1993.
308. NAGARAJAN, K, W. N. FISHBEIN, S. M. MULDOON, AND G. PEZESHKPOUR. Calcium uptake in frozen muscle biopsy sections compared with other predictors of malignant hyperthermia susceptibility. Anesthesiology 66: 680-685, 1987.
309. NALDA FELIPE, M. A., S. GOTTMANN, AND H. J. KHAMBATTA. Malignant Hyperthermia Current Concepts. Bad Homburg, Germany: Normed Verlag, 1989, p. 1-220.
310. NELSON, T. E. Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia. J. Clin. Invest. 72: 862-870, 1983.
311. NELSON, T. E. Dantrolene does not block calcium pulse-induced calcium release from a putative calcium channel in sarcoplasmic reticulum from malignant hyperthermia and normal pig muscle. Fed. Eur. Biochem. Soc. Lett. 167: 123-126, 1984.
312. NELSON, T. E. Skeletal muscle sarcoplasmic reticulum in the malignant hyperthermia syndrome. In: Malignant Hyperthermia, edited by B. A. Britt. Boston, MA: Martinus Nijhoff, 1987. p. 43-78.
313. NELSON, T. E. SR function in malignant hyperthermia. Cell Calcium 9: 257-265, 1988.
314. NELSON, T. E. Malignant hyperthermia in dogs. J. Am. Vet. Med. Assoc. 198: 989-994, 1991.
315. NELSON, T. E. Halothane effects on human malignant hyperthermia skeletal muscle single calcium-release channels in planar lipid bilayers. Anesthesiology 76: 588-595, 1992
316. NELSON, T. E., AND D. E. BEE. Temperature perturbation studies of sarcoplasmic reticulum from malignant hyperthermia pig muscle. J. Clin. Invest. 64: 895-901, 1979.
317. NELSON, T. E., E. H. FLEWELLEN, AND D. W. ARNETT. Prolonged electromechanical coupling time intervals in skeletal muscle of pigs susceptible to malignant hyperthermia Muscle Nerve 6: 263-268, 1983.
318. 2+ release from sarcoplasmic reticulum vesicles isolated from muscle of malignant hyperthermia diagnostic patients. J. Pharmacol. Exp. Ther. 240: 785-788, 1987.
319. NELSON, T. E., E. H. FLEWELLEN, AND D. F. GLOYNA. Spectrum of susceptibility of malignant hyperthermia-diagnostic dilemma. Anesth. Analg. 62: 545-552, 1983.
320. NELSON, T. E., E. W. JONES, J. H. VENABLE, AND D. D. KERR. Malignant hyperthermia of Poland China swine: studies of a myogenic etiology. Anesthesiology 36: 52-56, 1972.
321. NELSON, T. E., AND M. LIN. Abnormal function of porcine malignant hyperthermia calcium release channel in the absence and presence of halothane. Cell Physiol. Biochem. 5: 10-22, 1995.
322. 2+ regulatory site defect in sarcoplasmic reticulum from malignant hyperthermia pig muscle. J. Pharmacol. Exp. Ther. 256: 645-649, 1991.
323. NELSON, T. E., AND S. S. SCHOCKET, JR. Malignant hyperthermia: a disease of specific myofiber type? Can. Anaesth. Soc. J. 29: 163-167, 1982.
324. 2+ release by skeletal muscle sarcoplasmic reticulum: differing sensitivity to inhalational anesthetics. Anesthesiology 69: 571-577, 1988.
325. NIEBROJ-DOBOSZ, L, H. KWIATKOWSKI, AND E. MAYZNER-ZAWADZKA. Experimental porcine malignant hyperthermia: macromolecular characterization of muscle plasma membranes. Med. Biol. 62: 250-254, 1984.
326. NIEBEOJ-DOBOSZ, L, AND E. MAYZNER-ZAWADZKA. Experimental porcine malignant hyperthermia: the activity of certain transporting enzymes and myofibrillar calcium-binding protein content in the muscle fibre. Br. J. Anaesth. 54: 885-890, 1982.
327. O'BRIEN, P. J. Porcine malignant hyperthermia susceptibility: hypersensitive calcium-release mechanism of skeletal muscle sarcoplasmic reticulum. Can. J. Vet. Res. 50: 318-328, 1986.
328. O'BRIEN, P. J. Porcine malignant hyperthermia susceptibility: increased calcium-sequestering activity of skeletal muscle sarcoplasmic reticulum. Can. J. Vet. Res. 50: 329-337, 1986.
329. O'BRIEN, P. J. Microassay for malignant hyperthermia susceptibility: hypersensitive ligand-gating of the Ca channel in muscle sarcoplasmic reticulum causes increased amounts and rates of Ca-release. Mol. Cell. Biochem. 93: 53-59, 1990.
330. O'BRIEN, P. J. Canine malignant hyperthermia/canine stress syndrome. In: Malignant Hyperthermia, A Genetic Membrane Disease, edited by S. T. Ohnishi and T. Ohnishi. Boca Raton, FL: CRC, 1993, p. 105-116.
331. O'BRIEN, P. J., T. F. FLETCHER, A. L. METZ, M. J. KURTZ, B. K. REED, W. E. REMPEL, E. G. CLARK, AND C. F. LOUIS. Malignant hyperthermia susceptibility: cardiac histomorphometry of dogs and young market-weight swine. Can. J. Vet. Res. 51: 50-55, 1987.
332. O'BRIEN, P. J., B. I. KALOW, B. D. BROWN, J. H. LUMSDEN, AND R. M. JACOBS. Porcine malignant hyperthermia susceptibility: halothane-induced increase in cytoplasmic free calcium in lymphocytes. Am. J. Vet. Res. 50: 131-135, 1989.
333. OGAWA, Y. Role of ryanodine receptors. Crit. Rev. Biochem. Mol. Biol. 29: 229-274, 1994.
334. OHKOSHI, N., T. YOSHIZAWA, H. MIZUSAWA, S. SHOJI, M. TOYAMA, K IIDA, Y. SUGISHITA, K. HAMANO, A TAKAGI, K. GOTO, AND K. ARAHATA. Malignant hyperthermia in a patient with Becker muscular dystrophy: dystrophin analysis and caffeine contracture study. Neuromuscular Disorders 5: 53-58, 1995.
335. OHNISHI, S. T. Effects of halothane, caffeine, dantrolene and tetracaine on the calcium permeability of skeletal muscle sarcoplasmic reticulum of malignant hyperthermic pigs. Biochim. Biophys. Acta 897: 261-268, 1987.
336. OHNISHI, S. T., H. KATAGI, T. OHNISHI, AND A. K. W. BROWNELL. Detection of malignant hyperthermia susceptibility using spin label technique on red blood cells. Br. J. Anaesth. 61: 565-568, 1988.
337. OHNISHI, S. T., AND T. OHNISHI. Malignant Hyperthermia, A Genetic Membrane Disease Boca Raton, FL: CRC, 1993, 1-329.
338. 2+ release from sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia: the effects of halothane and dantrolene. Fed. Eur. Biochem. Soc. Lett. 161: 103-107, 1983.
339. OHNISHI, S. T., A. J. WARING, S.-R. G. FANG, K. HORIUCHI, J. L. FLICK, K. K. SADANAGA, AND T. OHNISHI. Abnormal membrane properties of the sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia: modes of action of halothane, caffeine, dantrolene, and two other drugs. Arch. Biochem. Biophys. 247: 294-301, 1986.
340. OIITA, T., M. ENDO, T. NAKANO, Y. MOROHOSHI, K. WANIKAWA, AND A. OHGA. Ca-induced Ca release in malignant hyperthermiasusceptible pig skeletal muscle. Am. J. Physiol. 256 (Cell Physiol. 25): C358-C367, 1989.
341. OKU, S., C.-C. LIEW, AND B. A. BRITT. Analysis of sarcoplasmic reticulum proteins in patients susceptible to malignant hyperthermia. J. Neurol. Sci. 60: 127-135, 1983.
342. OLCKERS, A, D. A. MEYERS, S. MEYERS, E. W. TAYLOR, J. E. FLETCHER, H. ROSENBERG, H, ISAACS, AND R. C. LEVTTT. Adult muscle sodium channel a-subunit is a gene candidate for malignant hyperthermia susceptibility. Genomics 14: 829-831, 1992.
343. OLGIN, J., Z. ARGOV, H. ROSEMBERG, M. TUCHLER, AND B. CHANCE. Non-invasive evaluation of malignant hyperthermia susceptibility and phosphorous nuclear magnetic resonance spectroscopy. Anesthesiology 68: 507-513, 1988.
344. ORDING, H. Incidence of malignant hyperthermia in Denmark. Anesth. Analg. 64: 700-704, 1985.
345. ORDING, H., AND D. BENDIXEN. Sources of variability in halothane and caffeine contractive tests for susceptibility to malignant hyperthermia. Eur. J. Anaesthesiol. 9: 367-376, 1992.
346. ORDING, H., U. HANSEN, AND L. T. SKOVGAARD. Age, fiber type composition and in vitro contracture responses in human malignant hyperthermia. Acta Anaesthesiol Scand 32. 121-124, 1988.
347. OTSU, K., J. FUJII, M. PERIASAMY, M. DIFILIPPANTONIO, M. UPPENDER, D. C. WARD, AND D. H. MACLENNAN. Chromosome mapping of five human cardiac and skeletal muscle sarcoplasmic reticulum protein genes. Genomics 17: 507-509, 1993.
348. OTSU, K., V. K. KHANNA, A. L. ARCHIBALD, AND D. H. MACLENNAN. Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families. Genomics 11: 744-750, 1991.
349. 2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia. J. Biol. Chem. 269: 9413-9415, 1994.
350. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J. Biol. Chem. 265: 13472-13483, 1990.
351. 2+ release. J. Biol. Chem. 262: 6135-6141, 1987.
352. PARNESS, J., AND S. S. PALNITKAR. Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 270: 18465-18472, 1995.
353. PHILLIPS, M. S., V. K. KHANNA, S. DELEON, W. FRODIS, B. A. BRITT, AND D. H. MACLENNAN. The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia. Hum. Mol. Genet. 3: 2181-2186, 1994.
354. PHILLIPS, M. S., AND D. H. MACLENNAN. The structure of the human skeletal muscle ryanodine receptor gene (RYR1) and its utility in screening for malignant hyperthermia mutations (Abstract). Am. J. Hum. Genet. 57: A224, 1995.
355. PTACEK, L. J., R. TAWIL, R. C. GREGGS, A. G. ENGEL, R. B. LAYZER, H. KWIECINSKI, P. G. McMANIS, L. SANTIAGO, M. MOORE, G. FAUAD, P. BRADLEY, AND M. F. LEPPERT. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 77: 863-868, 1994.
356. 2+ signalling in inexcitable cells. Science Wash. DC 262: 676-678, 1993.
357. QUANE, K. A., J. M. S. HEALY, K E. KEATING, B. M. MANNING, F. J. COUCH, L. M. PALMUCCI, C. DORIGUZZI, T. H. FAGERLUND, K. BERG, H. ORDING, D. BENDIXEN, W. MORTIER, U. LINZ, C. R. MULLER, AND T. V. McCARTHY. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genet. 5: 51-55, 1993.
358. QUANE, K. A., K. E. KEATING, J. M. S. HEALY, B. M. MANNING, R. KRIVOSIC-HORBER, I. KRIVOSIC, N. MONNIER, J. LUNARDI, AND T. V. McCARTHY. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 23: 236-239, 1994.
359. QUANE, K. A., K. E. KEATING, B. M. MANNING, J. M. S. HEALY, K. MONSIEURS, J. J. A. HEFFRON, M. LEHANE, L. HEYTENS, R. KRIVOSIC-HORBER, P. ADNET, F. R. ELLIS, N. MONNIER, J. LUNARDI, AND T. V. McCARTHY. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum. Mol. Genet. 3: 471-476, 1994.
360. QUINLAN, J. G., P. A. IAIZZO, G. A GRONERT, AND S. R. TAYLOR. Use of dantrolene plus multiple pulses to detect stress-susceptible porcine muscle. J. Appl. Physiol. 60: 1313-1320, 1986.
361. QUINLAN, J. G., P. A. IAIZZO, E. H. LAMBERT, AND G. A. GRONERT. Ankle dorsiflexor twitch properties in malignant hyperthermia. Muscle Nerve 12: 119-125, 1989.
362. QUINLAN, J. G., D. J. WEDEL, AND P. A. IAIZZO. Multiple-pulse stimulation and dantrolene in malignant hyperthermia Muscle Nerve 13: 904-908, 1990.
363. REIK, T. R., W. E. REMPEL, C. J. McGRATH, AND P. B. ADDIS. Further evidence on the inheritance of halothane reaction in pigs. J. Anim. Sci. 57: 826-831, 1983.
364. REISS, G., G. MONIN, AND C. LAUER. Comparative effects of the ionophore A23187 on the mechanical responses of muscle in normal Pietrain pigs and pigs with malignant hyperthermia. Can. J. Physiol. Pharmacol. 64: 248-253, 1986.
365. REMPEL, W. E., M. Y. LUE, J. R. MICKELSON, AND C. F. LOUIS. The effect of skeletal muscle ryanodine receptor genotype on swine performance and carcass quality traits. Anim. Sci. 60: 249-257, 1995.
366. RESKE-NIELSEN, E., J. HAASE, AND J. KELSTEUP. Malignant hyperthermia in a family. The ultrastructure of muscle biopsies of healthy members. Acta Pathol. Microbiol. Scand. Sect. A Pathol. 83: 645-650, 1975
367. RIOS, E., AND G. BRUM. Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle. Nature Lond. 325: 717-720, 1987.
368. RIOS, E., J. MA, AND A. GONZALEZ. The mechanical hypothesis of excitation-contraction (EC) coupling in skeletal muscle. J. Muscle Res. Cell Motil 12: 127-135, 1991.
369. RIOS, E., AND G. PIZARRO. Voltage sensor of excitation-contraction coupling in skeletal muscle. Physiol Rev. 71: 849-906, 1991.
370. 31P nuclear magnetic resonance (Abstract). Anesthesiology 59: A230, 1983.
371. 2+ transport system of surface membranes isolated from normal and malignant hyperthermia pig skeletal muscle. Arch. Biochem. Biophys. 256: 703-707, 1987.
372. ROCK, E., M. S. MAMMAR, X. VIGNON, M. A, THOMAS, AND J. VIRET. Abnormal fluidity state in membranes of malignant hyperthermia pig skeletal muscle. Arch. Biochem. Biophys. 281: 36-40, 1990.
373. 2+ release channel of skeletal muscle sarcoplasmic reticulum by caffeine and related compounds. Arch. Biochem. Biophys 267: 75-86, 1988.
374. RUITENBEEK, W., M. P. VERBERG, A. J. M. JANSSEN, A. M. STADHOUDERS, AND R. C. A. SENGERS. In vivo induced malignant hyperthermia in pigs. II. Metabolism of skeletal muscle mitochondria. Acta Anesthesiol. Scand. 28: 9-13, 1984.
375. RYAN, J. F., J. R. LOPEZ, V. B. SANCHEZ, F. A SRETER, AND P. D. ALLEN. Myoplasmic calcium changes precede metabolic and clinical signs of porcine malignant hyperthermia. Anesth. Analg. 79: 1007-1011, 1994.
376. SAIDMAN, L. J., E. S. HARVARD, AND E. EGER. Hyperthermia during anesthesia. J. Am. Med. Assoc. 190: 1029-1032, 1964.
377. SALVIATI, G., R. BETTO, S. CEOLDO, V. TEGAZZIN, AND A. D. PUPPA Caffeine sensitivity of sarcoplasmic reticulum of fast and slow fibers from normal and malignant hyperthermia human muscle. Muscle Nerve 12: 365-370, 1989.
378. SANCHEZ, J., AND E. STEFANI. Inward calcium current in twitch muscle fibers of the frog. J. Physiol. Lond. 283: 197-209, 1978.
379. SCHNEIDER, M. F. Control of calcium release in functioning skeletal muscle fibers. Annu. Rev. Physiol. 56: 463-484, 1994.
380. SCHOLZ, J., N. ROEWER, U. RUM, W. SCHMITZ, H. SCHOLZ, AND J. SCHULTE AM ESCH. Possible involvement of inositol-lipid metabolism in malignant hyperthermia. Br. J. Anaesth. 66: 692-696, 1991.
381. 2-adrenoceptors in skeletal and cardiac muscle. Acta Anaesth. Scand. 37: 575-583, 1993.
382. SCHOLZ, J., U. TROLL, J. SCHULTE AM ESCH, E. HARTUNG, M. PATTEN, P. SANDIG, AND W. SCHMITZ. Inositol-1,4,5-trisphosphate and malignant hyperthermia. Lancet 337: 1361, 1991.
383. SCHWEMMLE, S., K. WOLFF, L. M. PALMUCCI, T. GRIMM, F. LEHMANN-HORN, C. H. HUBNER, E. HAUSER, D. E. ILES, D. H. MACLENNAN, AND C. R. MULLER. Multipoint mapping of the central core disease locus. Genomics 17: 205-207, 1993.
384. SEEWALD, M. J., H. M. EICHINGER, AND P. A IAIZZO. Malignant hyperthermia: an altered phospholipid and fatty acid composition in muscle membranes. Acta Anaesthesiol. Scand. 35: 380-386, 1091.
385. SEEWALD, M. J., H. M. EICHINGER, F. LEHMANN-HORN, AND P. A IAIZZO. Characterization of swine susceptible to malignant hyperthermia by in vivo, in vitro and post-mortem techniques. Acta Anaesthesiol Scand. 35: 345-349, 1991.
386. SEWARD, D. J., AND T. A THOMAS. Intracellular calcium metabolism and malignant hyperpyrexia. In: International Symposium on Malignant Hyperthermia, edited by R. A. Gordon, B. A. Britt. and W. Kalow. Springfield, IL: Thomas, 1973, p. 409-414.
387. 2+ release channel (Abstract). Biophys. J. 68: A173, 1995.
388. SHOMER, N. H., C. F. LOUIS, M. FILL, L. A. LITTERER, AND J. R. MICKELSON. Reconstitution of abnormalities in the malignant hyperthermia-susceptible pig ryanodine receptor. Am. J. Physiol. 264 (Cell Physiol. 33): C125-C135, 1993.
389. 2+ release channels is unaffected by the Arg615 to Cys615 mutation. Biophys. J. 67: 641-646, 1994.
390. 2+ release channel. Am. J. Physiol. 267 (Cell Physiol. 36): C1253-C1261, 1994.
391. 2+ release channels of pigs heterozygous for malignant hyperthermia. Muscle Nerve 18: 1167-1176, 1995.
392. SIM, A T. R., M. D. WHITE, AND M. A DENBOROUGH. Effects of adenylate cyclase activators on porcine skeletal muscle in malignant hyperpyrexia. Br. J. Anaesth. 59: 1557-1562, 1987.
393. SMITH, J. S., R. CORONADO, AND G. MEISSNER. Sarcoplasmic reticulum contains adenine nucleotide-activated calcium channels Nature Lond. 316: 446-449, 1985.
394. SORRENTINO, V., AND P. VOLPE. Ryanodine receptors, how many, where and why. Trends Pharmacol. Sci. 14: 98-103, 1993.
395. SUAREZ-ISLA. B. A., V. IRRIBARRA, A. OBERHAUSER, L. LARRALDE, R. BULL, C. HIDALGO, AND E. JAIMOVICH. Inositol (1,4,5)-trisphosphate activates a calcium channel in isolated sarcoplasmic reticulum membranes. Biophys. J. 54: 737-741, 1988.
396. 1, and γ subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect. Hum. Mol. Genet. 2: 857-862, 1993.
397. SUDBRAK, R., V. PROCACCO, M. KLAUSNITZER, J. L. CHRRAN, K. MONSIEURS, C. VAN BROECKHOVEN, R. ELLIS, L. HEYETENS, E. J. HARTUNG, G. KOZAK-RIBBENS, D. HEILINGER, J. WEISSENBACK, F. LEHMAN-HORN, C. R. MUELLER, T. DEUFEL, A. D. STEWART, AND J. LUNARDI. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am. J. Hum. Genet. 56: 684-691, 1995.
398. SULLIVAN, J. S., AND M. A. DENBOROUGH. The isolation and chemical characterization of skeletal muscle microsomes from swine susceptible to malignant hyperpyrexia. Int. J. Biochem. 14: 741-745, 1982.
399. TAKAGI, A., N. SUNOHARA, T. ISHIHARA, I. NONAKA, AND H. SUGITA. Malignant hyperthermia and related neuromuscular diseases: caffeine contracture of the skinned muscle fibers Muscle Nerve 6: 510-514, 1983.
400. TAKESHIMA, H., S. NISHIMURA, T. MATSUMOTO, H. ISHIDA, K. KANGAWA, N. MINAMINO, H. MATSUO, M. UEDA, M. HANAOKA, T. HIROSE, AND S. NUMA. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature Lond. 339: 439-445, 1989.
401. TANABE, T., K. G. BEAM, J. A. POWELL, AND S. NUMA. Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor cDNA. Nature Lond. 336: 134-139, 1988.
402. TATE, C. A., M. F. MYEK, AND G. E. TAFFET. The role of calcium in the energetics of contracting skeletal muscle. Sports Med. 12: 208-217, 1991.
403. THATTE, H. S., P. A. ADDIS, D. D. THOMAS, D. J. BIGELOW, J. R. MICKELSON, AND C. F. LOUIS. Temperature-dependent abnormalities of the erythrocyte membrane in porcine malignant hyperthermia. Biochem. Med. Metab. Biol. 38: 366-377, 1987.
404. THOMAS, M. A., E. ROCK, AND J. VIRET. Membrane properties of the sarcolemma and sarcoplasmic reticulum of pigs susceptible to malignant hyperthermia Action of halothane. Clin. Chim. Acta 200: 201-210, 1991.
405. 2+ transients in cos-7 cells transfected with the cDNA encoding skeletal muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia. Biochem. J. 301: 661-665, 1994.
406. 2+ in the ryanodine receptor of human malignant hyperthermia. Am. J Physiol. 261 (Cell Physiol. 30): C237-C245, 1991.
407. VENABLE, J. H. Skeletal muscle structure in Poland China pigs suffering from malignant hyperthermia. In: International Symposium on Malignant Hyperthermia, edited by R A. Gordon, B. A. Britt, and W. Kalow. Springfield, IL: Thomas, 1973. p. 208-223.
408. VERBURG, M. P., B. A. BRITT, F. T. OERLEMANS, B. SCOTT, J. VAN EGMOND, AND D. H. DE BRUIJN. Comparison of metabolites in skeletal muscle biopsies from normal humans and those susceptible to malignant hyperthermia. Anesthesiology 65: 654-657, 1986.
409. 3H]ryanodine binding is not associated with malignant hyperthermia susceptibility in terminal cisternae preparations from swine. Biochem. Int. 23: 563-570, 1991.
410. VITA, G. M., A. OLCKERS, A. E. JEDLICKA, A. L. GEORGE, T. HELMAN-PATTERSON, H. ROSENBERG, J. E. FLETCHER, AND R. C. LEVITT. Masseter muscle rigidity associated with glycine 1306 to alanine mutation in the adult muscle sodium channel alpha subunit gene. Anethesiology 82: 1097-1103, 1995.
411. VLADUTIU, G. D., K. HOGAN, I. SAPONARA, L. TASSINI, AND J. CONROY. Carnitine palmitoyl transferase deficiency in malignant hyperthermia. Muscle Nerve 16: 485-491, 1993.
412. VOLPE, P., G. SALVIATI, F. DI VIRGIIO, AND T. POZZAN. Inositol 1,4,5-trisphosphate induces calcium release from sarcoplasmic reticulum of skeletal muscle. Nature Lond. 316: 347-349, 1985.
413. WALKER, J. W., A. V. SOMLYO, Y. E. GOLDMAN, A. P. SOMLYO, AND D. R. TRENTHAM. Kinetics of smooth and skeletal muscle activation by laser pulse photolysis of caged inositol 1,4,5-trisphosphate. Nature Lond. 327: 249-252, 1987.
414. WEBB, A. J. The halothane sensitivity test. In: Porcine Stress and Meat Quality - Causes and Possible Solutions to the Problems, edited by T. Froystein, E, Slinde, and N. Startdl. As, Norway: Agric. Food Res. Soc., 1981, p. 105-124.
415. WEBB, A. J., S. P. SIMPSON, AND O. I. SOUTHWOOD. Porcine stress syndrome: recent advances. In: Animal Health and Productivity Symposium, Royal Agricultural Society of England, Cambridge, UK, 1985, p. 143-464.
416. WEDEL, D. J. The effect of age on the development of MH in susceptible piglets (Abstract). Anesthesiology 81: A425, 1994.
417. WEDEL, D. J., AND T. E. NELSON. Malignant hyperthermia-diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone. Anesth. Analg. 78: 787-792, 1994.
418. WESTERBLAD, H., J. H. LEE, J. LANNEGREN, AND D. G. ALLEN. Cellular mechanisms of fatigue in skeletal muscle. Am. J. Physiol. 260 (Cell Physiol. 29): C615-C635, 1991.
419. WHITE, M. D., J. G. COLLINS, AND M. A. DENBOROUGH. The effect of dantrolene on skeletal-muscle sarcoplasmic-reticulum function in malignant hyperpyrexia in pigs. Biochem. J. 212: 399-405, 1983.
420. WIELAND, S. J., J. E. FLETCHER, H. ROSENBERG, AND Q. H. GONG. Malignant hyperthermia: slow sodium current in cultured human muscle cells. Am. J. Physiol. 257 (Cell Physiol. 26): C759-C765, 1989.
421. WILLIAMS, C. H. Some observations on the etiology of the fulminant hyperthermia stress syndrome. Perspect. Biol. Med. 20: 120-130, 1976.
422. WILLIAMS, C. H., S. E. DOZIER, AND W. BUZELLO. Plasma levels of norepinephrine and epinephrine during malignant hyperthermia in susceptible pigs. J. Chromatogr. 344: 71-80, 1985.
423. WILLIAMS, J. H., M. HOLLAND, J. C. LEE, C. W. WARD, AND C, J. McGRATH. BAY K 8644 and infedipine alter halothane but not caffeine contractures of malignant hyperthermic muscle fibers. Am. J. Physiol. 261 (Regulatory Integrative Comp. Physiol. 30): R782-R786, 1991.
424. WILLIAMS, J. H., M. HOLLAND, C. W. WARD, AND J. C. LEE. Altered mechanical responses of malignant hyperthermic skeletal muscle during repetitive stimulation. J. Physiol. Lond. 86: 159-165, 1992.
425. WILLNER, J. H., C. G. CERRI, AND D. S. WOOD. High skeletal muscle adenylate cyclase in malignant hyperthermia. J. Clin. Invest. 68: 1119-1124, 1981.
426. WINGARD, D. W. Malignant hyperthermia: a human stress syndrome? Lancet 4: 1450-1451, 1974.
427. WOOD, D. S., J. H. WILLNER, AND G. SALVIATI. Malignant hyperthermia: the pathogenesis of abnormal caffeine contracture. In: Disorders of the Motor Unit, edited by D. L. Schotland. New York: Wiley, 1982. p. 597.
428. YANG, H. C., M. M. REEDY, C. L. BURKE, AND G. M. STRASBURG. Calmodulin interaction with the skeletal muscle sarcoplasmic reticulum calcium channel protein. Biochemistry 33: 518-525, 1994.
429. YANG, H. C., M. M. REEDY. J. R. MICKELSON, C. F. LOUIS, AND G. M. STRASBURG. Calmodulin interaction with the SR calcium channel protein in normal and malignant hyperthermia susceptible muscle (Abstract). Biophys. J. 64: A303, 1993.
430. ZHANG, W., D. L. KUHLERS, AND W. E. REMPEL Halothane gene and swine performance. J. Anim. Sci. 70: 1307-1313, 1992.
431. ZHANG, Y., H. S. CHEN, V. K. KHANNA, S. DE LEON, M. S. PHILLIPS, K. SCHAPPERT, B. A. BRITT, A. K. W. BROWNELL, AND D. H. MACLENNAN. A mutation in the human ryanodine receptor gene associated with central core disease. Nature Genet. 5: 46-50, 1993.
432. 2+-ATPase of human fast-twitch skeletal muscle sacroplasmic reticulum, and its elimination as a candidate gene for Brody's disease. Genomics 30: 415-424, 1995.
433. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 265: 2244-2256, 1990.
434. 2+ release. Mol. Pharmacol. 44: 1192-1201, 1993.